Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by First Trust Advisors LP

First Trust Advisors LP reduced its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 37.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 149,148 shares of the biotechnology company’s stock after selling 88,582 shares during the period. First Trust Advisors LP’s holdings in Arrowhead Pharmaceuticals were worth $9,352,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Tsfg LLC acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at $25,000. First Horizon Corp acquired a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $32,000. WPG Advisers LLC boosted its position in shares of Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 431 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 177.1% in the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 471 shares during the last quarter. Finally, Elyxium Wealth LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $54,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the sale, the director owned 52,012 shares in the company, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ARWR shares. Piper Sandler restated an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Chardan Capital increased their price target on shares of Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. B. Riley Financial raised their price objective on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a report on Thursday. Sanford C. Bernstein boosted their price objective on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, Morgan Stanley boosted their price objective on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $96.92.

Arrowhead Pharmaceuticals Stock Down 3.1%

ARWR opened at $84.65 on Friday. The business’s 50-day simple moving average is $79.04 and its 200-day simple moving average is $70.67. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. Arrowhead Pharmaceuticals, Inc. has a one year low of $15.01 and a one year high of $95.49. The stock has a market capitalization of $11.92 billion, a P/E ratio of -39.37 and a beta of 1.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The business’s revenue was down 86.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.75 EPS. Analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.08 EPS for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.